JOP20200277B1 - مركبات تثبيط rip1 وطرق لتحضير واستخدامها - Google Patents
مركبات تثبيط rip1 وطرق لتحضير واستخدامهاInfo
- Publication number
- JOP20200277B1 JOP20200277B1 JOJO/P/2020/0277A JOP20200277A JOP20200277B1 JO P20200277 B1 JOP20200277 B1 JO P20200277B1 JO P20200277 A JOP20200277 A JO P20200277A JO P20200277 B1 JOP20200277 B1 JO P20200277B1
- Authority
- JO
- Jordan
- Prior art keywords
- rip1
- kinase
- inhibitors
- preparation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666452P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030473 WO2019213445A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20200277A1 JOP20200277A1 (ar) | 2020-11-03 |
| JOP20200277B1 true JOP20200277B1 (ar) | 2024-04-18 |
Family
ID=66554488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2020/0277A JOP20200277B1 (ar) | 2018-05-03 | 2020-11-03 | مركبات تثبيط rip1 وطرق لتحضير واستخدامها |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| UA128160C2 (uk) | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| KR102793185B1 (ko) | 2019-09-06 | 2025-04-09 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| AU2020378407B2 (en) * | 2019-11-07 | 2024-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
| JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| AU2021329777A1 (en) * | 2020-08-18 | 2023-03-09 | Hutchison Medipharma Limited | Pyrimidinone compounds and uses thereof |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| TW202311261A (zh) * | 2021-05-14 | 2023-03-16 | 大陸商中國醫藥研究開發中心有限公司 | 氮呯類稠環化合物及其醫藥用途 |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| EP4422621A4 (en) * | 2021-10-27 | 2025-08-27 | Merck Sharp & Dohme Llc | SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF |
| KR20230100646A (ko) * | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| US20250179061A1 (en) * | 2022-02-28 | 2025-06-05 | Sironax Ltd. | Rip1 modulators, preparations, and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| EP0431519B1 (en) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | System for transdermal albuterol administration |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| DE69228827T2 (de) | 1991-12-18 | 1999-10-21 | Minnesota Mining And Mfg. Co., Saint Paul | Mehrschichtige sperrstrukturen |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
| RU2017109122A (ru) * | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| CN107207485A (zh) | 2015-02-13 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | (S)‑5‑苄基‑N‑(5‑甲基‑4‑氧代‑2,3,4,5‑四氢苯并[b][1,4]氧氮杂环庚三烯‑3‑基)‑4H‑1,2,4‑三唑‑3‑甲酰胺的晶型 |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| US10426758B2 (en) | 2015-10-13 | 2019-10-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MA44007A (fr) * | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (en) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| UA128160C2 (uk) | 2018-05-03 | 2024-04-24 | Райджел Фармасутікалс, Інк. | Сполуки, що інгібують rip1, а також способи їх одержання та застосування |
| EA202092580A1 (ru) | 2018-05-03 | 2021-04-07 | Ригел Фармасьютикалз, Инк. | Соединения, ингибирующие rip1, а также способы их получения и применения |
| EP3816163A4 (en) | 2018-06-26 | 2022-04-13 | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences | CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| KR102793185B1 (ko) | 2019-09-06 | 2025-04-09 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| AU2020378407B2 (en) * | 2019-11-07 | 2024-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclic RIP1 inhibitory compounds |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 UA UAA202007282A patent/UA128160C2/uk unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142B2/en active Active
- 2019-05-02 KR KR1020207034544A patent/KR102823195B1/ko active Active
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 SM SM20230203T patent/SMT202300203T1/it unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/en not_active Ceased
- 2019-05-02 CA CA3099018A patent/CA3099018A1/en active Pending
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/en active Active
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 CN CN201980045150.5A patent/CN112384510B/zh active Active
- 2019-05-02 MY MYPI2020005729A patent/MY205388A/en unknown
-
2020
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-03 JO JOJO/P/2020/0277A patent/JOP20200277B1/ar active
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
-
2024
- 2024-02-05 US US18/432,727 patent/US20240217958A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200277B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| JOP20220056A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
| MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| WO2014194254A8 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| UA117830C2 (uk) | Похідні біпіразолу як інгібітори jak | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| TW201613577A (en) | Pharmaceutical combinations | |
| JOP20220355A1 (ar) | مثبطات rip1k | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| NZ738247A (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors |